trending Market Intelligence /marketintelligence/en/news-insights/trending/WbQKvTPvYDOlxWNoMdSCiQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Equillium's kidney drug gets US FDA fast-track designation for type of lupus

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Equillium's kidney drug gets US FDA fast-track designation for type of lupus

The U.S. Food and Drug Administration has granted fast-track designation to Equillium Inc.'s itolizumab for treating kidney inflammation in lupus patients.

Fast-track designation gives regulatory priority to treatments that show promise, including frequent meetings with the FDA and priority review of the marketing application.

The San Diego-based biotechnology company started a phase 1b study called Equalise in September to evaluate the drug to treat patients with lupus and lupus nephritis.

Lupus is a chronic autoimmune disease that causes damage to the skin, joints and organs. Lupus nephritis specifically involves the kidneys, affecting about 100,000 patients in the U.S.